Drug Trial Radar · NCT05960240
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Aug 30, 2023
Primary completion
Dec 4, 2025
Study completion Feb 9, 2026
Sponsor
- Lead sponsor
- Arbutus Biopharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-101 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.
Conditions
- Chronic Hepatitis b
Interventions
AB-101Drug
AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
PlaceboDrug
A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
Nucleos(t)ide AnalogueDrug
Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2: Incidence of adverse events (AEs), serious AEs (SAEs), immune related AEs (irAEs) and discontinuations due to AEs and irAEs.Time frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]
- Part 3: Incidence of AEs, SAEs, irAEs and discontinuations due to AEs and irAEsTime frame: [Time Frame: Up to 196 days]
- Parts 1 and 2: Incidence of clinically significant laboratory abnormalities Parts 1 and 2: Incidence of clinically significant laboratory abnormalitiesTime frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]
- Parts 1 and 2: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs)Time frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]
- Part 3: Incidence of clinically significant laboratory abnormalitiesTime frame: [Time Frame: Up to 196 days]
- Part 3: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs)Time frame: [Time Frame: Up to 196 days]
Locations
10 sites in 7 countries. Site status is shown where the registry gives one.
Prince of Wales Hospital
Hong Kong, Hong Kong, Hong Kong
Queen Mary Hospital - PPDS
Hong Kong, Hong Kong, Hong Kong
ASST Papa Giovanni XXIII -Osepedale
Bergamo, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan, Italy
Clinial Republican Hospital "Timofei Mosneaga"
Chisinau, Moldova
New Zealand Clinical Research Auckland
Grafton, Auckland, New Zealand
Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E. M.
Bucharest, Romania
National University Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council
Kyiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.